Suppr超能文献

p53 转录程序的激活使癌细胞对 CDK7 抑制剂敏感。

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.

机构信息

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Cell Rep. 2017 Oct 10;21(2):467-481. doi: 10.1016/j.celrep.2017.09.056.

Abstract

Cdk7, the CDK-activating kinase and transcription factor IIH component, is a target of inhibitors that kill cancer cells by exploiting tumor-specific transcriptional dependencies. However, whereas selective inhibition of analog-sensitive (AS) Cdk7 in colon cancer-derived cells arrests division and disrupts transcription, it does not by itself trigger apoptosis efficiently. Here, we show that p53 activation by 5-fluorouracil or nutlin-3 synergizes with a reversible Cdk7 inhibitor to induce cell death. Synthetic lethality was recapitulated with covalent inhibitors of wild-type Cdk7, THZ1, or the more selective YKL-1-116. The effects were allele specific; a CDK7 mutation conferred both sensitivity to bulky adenine analogs and resistance to covalent inhibitors. Non-transformed colon epithelial cells were resistant to these combinations, as were cancer-derived cells with p53-inactivating mutations. Apoptosis was dependent on death receptor DR5, a p53 transcriptional target whose expression was refractory to Cdk7 inhibition. Therefore, p53 activation induces transcriptional dependency to sensitize cancer cells to Cdk7 inhibition.

摘要

Cdk7,即 CDK 激活激酶和转录因子 IIH 成分,是一种抑制剂的靶标,这些抑制剂通过利用肿瘤特异性转录依赖性来杀死癌细胞。然而,尽管在源自结肠癌的细胞中选择性抑制模拟物敏感(AS)Cdk7 会阻止细胞分裂并破坏转录,但它本身并不能有效地触发细胞凋亡。在这里,我们表明,5-氟尿嘧啶或 nutlin-3 激活 p53 与可逆的 Cdk7 抑制剂协同作用以诱导细胞死亡。用野生型 Cdk7 的共价抑制剂 THZ1 或更具选择性的 YKL-1-116 重现了合成致死性。这些效果具有等位基因特异性;CDK7 突变赋予了对大体积腺嘌呤类似物的敏感性和对共价抑制剂的抗性。未转化的结肠上皮细胞对这些组合具有抗性,具有 p53 失活突变的癌症衍生细胞也是如此。细胞凋亡依赖于死亡受体 DR5,DR5 是 p53 的转录靶标,其表达对 Cdk7 抑制具有抗性。因此,p53 激活诱导转录依赖性,使癌细胞对 Cdk7 抑制敏感。

相似文献

1
Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Cell Rep. 2017 Oct 10;21(2):467-481. doi: 10.1016/j.celrep.2017.09.056.
2
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Oncogene. 2020 Jan;39(1):50-63. doi: 10.1038/s41388-019-0953-9. Epub 2019 Aug 28.
3
THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Cell Commun Signal. 2022 Sep 8;20(1):138. doi: 10.1186/s12964-022-00928-x.
6
THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Oncogene. 2019 May;38(20):3932-3945. doi: 10.1038/s41388-019-0701-1. Epub 2019 Jan 28.
7
CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12986-12995. doi: 10.1073/pnas.1815780116. Epub 2019 Jun 10.
8
Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
J Cell Biochem. 2018 Dec;119(12):9742-9751. doi: 10.1002/jcb.27292. Epub 2018 Aug 26.
9
The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
Nucleic Acids Res. 2019 May 7;47(8):3921-3936. doi: 10.1093/nar/gkz127.
10
Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
Oral Dis. 2022 Apr;28(3):611-620. doi: 10.1111/odi.13783. Epub 2021 Feb 6.

引用本文的文献

1
The involvement of cyclin-dependent kinase 7 (CDK7) and 9 (CDK9) in coordinating transcription and cell cycle checkpoint regulation.
Cell Cycle. 2024 Nov-Dec;23(21-24):962-974. doi: 10.1080/15384101.2025.2485844. Epub 2025 Apr 14.
2
TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network.
Sci Adv. 2025 Feb 28;11(9):eadr9660. doi: 10.1126/sciadv.adr9660.
4
Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer.
Future Oncol. 2024 Dec;20(40):3519-3537. doi: 10.1080/14796694.2024.2419352. Epub 2024 Nov 12.
5
Global trends and topics in CDK7 inhibitor research: a bibliometric analysis.
Front Pharmacol. 2024 Sep 25;15:1426988. doi: 10.3389/fphar.2024.1426988. eCollection 2024.
6
CDK7 in breast cancer: mechanisms of action and therapeutic potential.
Cell Commun Signal. 2024 Apr 11;22(1):226. doi: 10.1186/s12964-024-01577-y.
8
Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
Br J Cancer. 2024 May;130(8):1239-1248. doi: 10.1038/s41416-024-02589-8. Epub 2024 Feb 14.
9
Inhibition of CDK12 elevates cancer cell dependence on P-TEFb by stimulation of RNA polymerase II pause release.
Nucleic Acids Res. 2023 Nov 10;51(20):10970-10991. doi: 10.1093/nar/gkad792.
10
Cyclin-dependent kinases: Masters of the eukaryotic universe.
Wiley Interdiscip Rev RNA. 2023 Sep 17;15(1):e1816. doi: 10.1002/wrna.1816.

本文引用的文献

2
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Nat Chem Biol. 2016 Oct;12(10):876-84. doi: 10.1038/nchembio.2166. Epub 2016 Aug 29.
3
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Nature. 2016 Sep 1;537(7618):112-116. doi: 10.1038/nature19327. Epub 2016 Aug 24.
4
Engineered Covalent Inactivation of TFIIH-Kinase Reveals an Elongation Checkpoint and Results in Widespread mRNA Stabilization.
Mol Cell. 2016 Aug 4;63(3):433-44. doi: 10.1016/j.molcel.2016.06.036. Epub 2016 Jul 28.
5
CDK7-dependent transcriptional addiction in triple-negative breast cancer.
Cell. 2015 Sep 24;163(1):174-86. doi: 10.1016/j.cell.2015.08.063.
6
THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
Mol Cell. 2015 Aug 20;59(4):576-87. doi: 10.1016/j.molcel.2015.06.032. Epub 2015 Aug 6.
7
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.
Cancer Cell. 2014 Dec 8;26(6):909-922. doi: 10.1016/j.ccell.2014.10.019.
8
Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex.
J Biol Chem. 2015 Jan 16;290(3):1786-95. doi: 10.1074/jbc.M114.612226. Epub 2014 Nov 26.
9
CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Cell. 2014 Nov 20;159(5):1126-1139. doi: 10.1016/j.cell.2014.10.024. Epub 2014 Nov 6.
10
BEDTools: The Swiss-Army Tool for Genome Feature Analysis.
Curr Protoc Bioinformatics. 2014 Sep 8;47:11.12.1-34. doi: 10.1002/0471250953.bi1112s47.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验